When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?

Trends in Molecular Medicine

Volumn 15, Issue 1, 2009, Pages 1-4

  Soussi, Thierry ^a,b   Hjortsberg, Linn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEFITINIB; IMATINIB; PROTEIN MDM2; PROTEIN P53;

CANCER CELL; EXPERIMENTAL MODEL; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; HUMAN; METASTASIS; MISSENSE MUTATION; NEOPLASM; NONHUMAN; SHORT SURVEY; TUMOR;

ANIMALS; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION; HUMANS; MICE; MUTATION, MISSENSE; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

MUS;

EID: 58149505704     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.11.002     Document Type: Short Survey

References (21)

1. Soussi T., and Wiman K.G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12 (2007) 303-312
2. Vogelstein B., et al. Surfing the p53 network. Nature 408 (2000) 307-310
3. Riley T., et al. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9 (2008) 402-412
4. Zong W.X., and Moll U. p53 in autophagy control. Cell Cycle 7 (2008) 2947
5. Tasdemir E., et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 10 (2008) 676-687
6. Soussi T., et al. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 6 (2006) 83-90
7. Hall P.A., and McCluggage W.G. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. J. Pathol. 208 (2006) 1-6
8. Iwakuma T., et al. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 4 (2005) 865-867
9. Weisz L., et al. Transcription regulation by mutant p53. Oncogene 26 (2007) 2202-2211
10. Li Y., and Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 26 (2007) 2220-2225
11. Johnson T.M., and Attardi L.D. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice. Cell Death Differ. 13 (2006) 902-908
12. Olive K.P., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119 (2004) 847-860
13. Lang G.A., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 (2004) 861-872
14. INK4a loss. Genes Dev. 22 (2008) 1337-1344
15. Sjogren S., et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88 (1996) 173-182
16. Casey G., et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13 (1996) 1971-1981
17. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
18. Montes de Oca Luna R., et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378 (1995) 203-206
19. Selivanova G., and Wiman K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26 (2007) 2243-2254
20. Bassett E.A., et al. Structural and functional basis for therapeutic modulation of p53 signaling. Clin. Cancer Res. 14 (2008) 6376-6386
21. Rubin B.P., and Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab. Invest. 86 (2006) 981-986